Minerva Neurosciences:研发及管理成本可能上升,但我们有良好条件为Roluperidone在美国的第三阶段、NDA重新提交与上市准备提供资金

美股速递
Nov 05, 2025

Minerva Neurosciences:研发及管理成本可能上升,但我们有良好条件为Roluperidone在美国的第三阶段、NDA重新提交与上市准备提供资金

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10